Rescuing clinical trials in the United States and beyond: A call for action
Authors:
- Zubin J. EapenZEZubin J. Eapen
- John P. VavalleJVJohn P. Vavalle
- Christopher B. GrangerCGChristopher B. Granger
- Robert A. HarringtonRHRobert A. Harrington
- Eric D. PetersonEPEric D. Peterson
- Robert M. CaliffRCRobert M. Califf
- 1 June 2013
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 165 (6) , 837-847
Abstract
No abstract availableKeywords
Funding Information
- Abbott Laboratories
- American College of Cardiology Foundation
- American Heart Association
- Society of Thoracic Surgeons
This publication has 35 references indexed in Scilit:
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) TrialCirculation, 2011
- American Industry and the U.S. Cardiovascular Clinical Research EnterpriseJACC, 2011
- International Participation in Cardiovascular Randomized Controlled Trials Sponsored by the National Heart, Lung, and Blood InstituteJACC, 2011
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2009
- Scientific Evidence Underlying the ACC/AHA Clinical Practice GuidelinesJAMA, 2009
- Ethical and Scientific Implications of the Globalization of Clinical ResearchNew England Journal of Medicine, 2009
- Financial Anatomy of Biomedical ResearchJAMA, 2005
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- Cost of innovation in the pharmaceutical industryJournal of Health Economics, 1991